GBP1P1: A Potential Drug Target and Biomarker for Diseases (G400759)

Target Name: GBP1P1

NCBI ID: G400759

GBP1P1

Other Name(s): Guanylate binding protein 1 pseudogene 1 | guanylate binding protein 1 pseudogene 1 | LIMIT

GBP1P1: A Potential Drug Target and Biomarker for Diseases

GBP1P1, also known as Guanylate binding protein 1 pseudogene 1, is a protein that is expressed in various tissues and cells throughout the body. It is a member of the GBP family, which is known for its role in cell signaling and signaling pathways. GBP1P1 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The GBP1P1 protein is involved in a number of cellular processes that are important for normal cellular function. One of its main functions is to regulate the levels of intracellular calcium ions, which are critical for many cellular processes, including muscle contractions, nerve signaling, and cell signaling. GBP1P1 helps to regulate the levels of calcium ions by interacting with a protein called TRPV4, which is involved in the sense of touch.

In addition to its role in calcium ion regulation, GBP1P1 is also involved in the regulation of cellular signaling pathways. It has been shown to play a role in the signaling pathway that regulates cell proliferation, and it has been shown to interact with proteins involved in the pathway, including the oncogene PDGF-A.

As a potential drug target, GBP1P1 is of interest because of its involvement in cellular signaling pathways. Drugs that target GBP1P1 have the potential to interfere with these pathways and disrupt cellular function. This could lead to a wide range of potential therapeutic benefits, including the treatment of cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential therapeutic applications, GBP1P1 is also of interest as a biomarker for various diseases. Its involvement in cellular signaling pathways makes it a potential target for diagnostic tests that are used to monitor the effectiveness of drugs. For example, studies have shown that GBP1P1 is expressed in various tissues and cells and that it is involved in the regulation of cellular signaling pathways. These findings suggest that GBP1P1 may be a useful biomarker for diseases in which the disruption of cellular signaling pathways is a key feature.

Overall, GBP1P1 is a protein that is of interest as a potential drug target and biomarker. Its involvement in cellular signaling pathways and its potential therapeutic applications make it a promising target for the development of new treatments for a wide range of diseases. Further research is needed to fully understand the role of GBP1P1 in cellular signaling pathways and its potential as a drug target and biomarker.

Protein Name: Guanylate Binding Protein 1 Pseudogene 1

The "GBP1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GBP1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets